CN100551441C - 包含脑膜炎奈瑟球菌血清群b和c抗原和其它抗原的组合物 - Google Patents
包含脑膜炎奈瑟球菌血清群b和c抗原和其它抗原的组合物 Download PDFInfo
- Publication number
- CN100551441C CN100551441C CNB008187126A CN00818712A CN100551441C CN 100551441 C CN100551441 C CN 100551441C CN B008187126 A CNB008187126 A CN B008187126A CN 00818712 A CN00818712 A CN 00818712A CN 100551441 C CN100551441 C CN 100551441C
- Authority
- CN
- China
- Prior art keywords
- composition
- protein
- antigen
- compositions
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
2996 | BZ133 | BZ232 | 1000 | MC58 | NGH38 | |
三元混合物 | 2048 | 2048 | 4 | <4 | 64 | 4 |
+NmC | 2048 | >32000 | 4 | 128 | 1024 | 128 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910170925.XA CN101822830B (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9928196.6A GB9928196D0 (en) | 1999-11-29 | 1999-11-29 | Combinations of B, C and other antigens |
GB9928196.6 | 1999-11-29 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910170925.XA Division CN101822830B (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原的组合物 |
CNA2003101046748A Division CN1507916A (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原和其它抗原的组合物 |
CN2009100081173A Division CN101549154B (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1433322A CN1433322A (zh) | 2003-07-30 |
CN100551441C true CN100551441C (zh) | 2009-10-21 |
Family
ID=10865363
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910170925.XA Expired - Fee Related CN101822830B (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原的组合物 |
CN2009100081173A Expired - Fee Related CN101549154B (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原的组合物 |
CNB008187126A Expired - Fee Related CN100551441C (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原和其它抗原的组合物 |
CNA2003101046748A Pending CN1507916A (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原和其它抗原的组合物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910170925.XA Expired - Fee Related CN101822830B (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原的组合物 |
CN2009100081173A Expired - Fee Related CN101549154B (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原的组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003101046748A Pending CN1507916A (zh) | 1999-11-29 | 2000-11-29 | 包含脑膜炎奈瑟球菌血清群b和c抗原和其它抗原的组合物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9636393B2 (zh) |
EP (3) | EP2289599A3 (zh) |
JP (5) | JP5670003B2 (zh) |
CN (4) | CN101822830B (zh) |
AT (1) | ATE427756T1 (zh) |
AU (2) | AU784375B2 (zh) |
BR (1) | BR0015958A (zh) |
CA (2) | CA2762106C (zh) |
CY (1) | CY1109202T1 (zh) |
DE (1) | DE60041981D1 (zh) |
DK (1) | DK1235589T3 (zh) |
ES (1) | ES2322753T3 (zh) |
GB (1) | GB9928196D0 (zh) |
MX (1) | MXPA02005322A (zh) |
NZ (2) | NZ519608A (zh) |
PT (1) | PT1235589E (zh) |
RU (2) | RU2361609C2 (zh) |
WO (1) | WO2001037863A2 (zh) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
DE69529219T2 (de) * | 1994-07-01 | 2003-11-06 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Helicobacter proteine und impstoffe |
PT909323E (pt) * | 1996-01-04 | 2007-06-04 | Novartis Vaccines & Diagnostic | ''bacterioferritina de helicobacter pilori'' |
WO1998012332A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
AU2457100A (en) * | 1999-02-26 | 2000-09-14 | Chiron S.P.A. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs |
KR20030024811A (ko) | 2000-07-27 | 2003-03-26 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
BR0211494A (pt) | 2001-07-27 | 2004-08-17 | Chiron Srl | Adesinas de meningococo nada, app e orf 40 |
US20050175629A1 (en) * | 2001-08-31 | 2005-08-11 | Giuseppe Del Giudice | Helicobacter pylori vaccination |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
CN102302776B (zh) * | 2003-01-30 | 2014-06-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
DE602004032481D1 (de) * | 2003-10-02 | 2011-06-09 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen Meningitis |
CU23236A1 (es) * | 2003-12-03 | 2007-09-26 | Ct Ingenieria Genetica Biotech | PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0409750D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Integration of meningococcal conjugate vaccination |
EP1855715B1 (en) | 2005-01-27 | 2013-03-13 | Children's Hospital & Research Center at Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
CN101590225B (zh) * | 2009-06-19 | 2012-02-15 | 长春长生生物科技股份有限公司 | 百白破、A+C群脑膜炎球菌-b型流感嗜血杆菌结合疫苗 |
ES2663872T3 (es) * | 2010-03-11 | 2018-04-17 | Glaxosmithkline Biologicals S.A. | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria |
CA2808975C (en) | 2010-08-23 | 2018-10-30 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
JP5976652B2 (ja) | 2010-09-10 | 2016-08-24 | ワイス・エルエルシー | 髄膜炎菌orf2086抗原の非脂質化変異体 |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
CN104334187B (zh) | 2012-03-09 | 2017-04-05 | 辉瑞公司 | 脑膜炎双球菌组合物及其方法 |
US9526776B2 (en) | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
WO2015033251A2 (en) | 2013-09-08 | 2015-03-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
MA40974B1 (fr) * | 2014-11-18 | 2021-02-26 | Pasteur Institut | Anticorps polyclonaux spécifiques pour le sérogroupe x de n. Meningitidis et leurs utilisations dans le diagnostic |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
SG11201901394XA (en) | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
KR102567845B1 (ko) | 2017-01-31 | 2023-08-17 | 화이자 인코포레이티드 | 네이세리아 메닌기티디스 조성물 및 그의 방법 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
EP0273116A3 (en) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Gonococcal and meningococcal polypeptides, vaccines and diagnostics |
US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
ATE121947T1 (de) * | 1989-12-14 | 1995-05-15 | Ca Nat Research Council | Verbessertes meningokokkale polysaccharidkonjugatvakzin. |
IE912559A1 (en) | 1990-07-19 | 1992-01-29 | Merck & Co Inc | The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same |
US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
WO1992016643A1 (en) | 1991-03-14 | 1992-10-01 | Imclone Systems Incorporated | Recombinant hybrid porin epitopes |
HU220236B (hu) | 1992-05-23 | 2001-11-28 | Smithkline Beecham Biologicals S.A. | Hepatitis B felszíni antigént és egyéb antigéneket tartalmazó, kombinált oltóanyagok |
FR2692592B1 (fr) * | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
US6290962B1 (en) * | 1992-11-03 | 2001-09-18 | Oravax, Inc. | Urease-based vaccine and treatment for helicobacter infection |
ES2145072T3 (es) * | 1993-05-13 | 2000-07-01 | American Cyanamid Co | Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos. |
US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
EP0710118B1 (en) * | 1994-04-20 | 1998-11-25 | U.S. Department Of The Army | Vaccine against gram-negative bacterial infections |
FR2720408B1 (fr) | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
JPH11502222A (ja) * | 1995-03-23 | 1999-02-23 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 遺伝子供給用ベクター |
US6180111B1 (en) * | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
DK1082965T3 (da) | 1995-06-23 | 2009-07-27 | Glaxosmithkline Biolog Sa | Et vaccinepræparat der omfatter et polysaccharidkonjugatantigen adsorberet på aluminiumphosphat |
FR2739624B1 (fr) | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | Nouvelle sous-unite tbp2 de neisseria meningitidis |
AU2115897A (en) * | 1996-02-01 | 1997-08-22 | North American Vaccine, Inc. | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
US6558677B2 (en) * | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
EP0994723A1 (en) * | 1997-06-24 | 2000-04-26 | Chiron Corporation | Methods of immunizing adults using anti-meningococcal vaccine compositions |
CN1272062A (zh) * | 1997-07-17 | 2000-11-01 | 北美疫苗公司 | 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物 |
BR9813930A (pt) * | 1997-11-06 | 2006-12-19 | Chiron Spa | antìgeno neisserial |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
CN101293920B (zh) | 1998-05-01 | 2012-07-18 | 诺华疫苗和诊断公司 | 脑膜炎奈瑟球菌抗原和组合物 |
GB9810276D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
EP1741443B1 (en) | 1998-05-29 | 2014-05-21 | Novartis Vaccines and Diagnostics, Inc. | Combination meningitidis B/C vaccines |
ES2278446T3 (es) * | 1998-05-29 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Vacunas combinadas b/c contra la meningitis. |
JP2004511201A (ja) | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
BR0010130A (pt) | 1999-04-30 | 2002-06-04 | Chiron Spa | Antìgenos de neisseria conservados |
BR0010361A (pt) | 1999-04-30 | 2003-06-10 | Chiron Corp | Seq ências genÈmicas de neisseria e uso destas |
EP1179072A2 (en) | 1999-05-19 | 2002-02-13 | Chiron S.P.A. | Combination neisserial compositions |
MXPA02004283A (es) | 1999-10-29 | 2002-10-17 | Chiron Spa | Peptidos antigenicos neisseriales. |
AU1917501A (en) | 1999-11-12 | 2001-06-06 | University Of Iowa Research Foundation, The | Control of neisserial membrane synthesis |
BRPI0107679B8 (pt) | 2000-01-17 | 2021-05-25 | Chiron Spa | composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma |
EP1252182B1 (en) | 2000-01-25 | 2012-06-20 | The University Of Queensland | PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA |
ATE352631T1 (de) | 2000-02-28 | 2007-02-15 | Novartis Vaccines & Diagnostic | Heterologe expression von neisseria proteine |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
KR20030024811A (ko) * | 2000-07-27 | 2003-03-26 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신 |
JP2005504718A (ja) | 2001-01-23 | 2005-02-17 | アヴェンティス パストゥール | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
EP1409013B1 (en) | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
BR0211494A (pt) | 2001-07-27 | 2004-08-17 | Chiron Srl | Adesinas de meningococo nada, app e orf 40 |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
KR101140033B1 (ko) | 2002-08-02 | 2012-05-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
DE60335477D1 (de) * | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
CA2506318C (en) | 2002-11-15 | 2011-07-12 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004054611A1 (en) | 2002-12-16 | 2004-07-01 | Nasjonalt Folkehelseinstitutt | Meningococcal vaccine based on outer membrane proteins porb2 and pora |
CN102302776B (zh) * | 2003-01-30 | 2014-06-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
BRPI0410341B8 (pt) | 2003-05-07 | 2021-05-25 | Sanofi Pasteur Inc | conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
DE602004032481D1 (de) * | 2003-10-02 | 2011-06-09 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen Meningitis |
WO2005064021A2 (en) | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | Vaccine |
GB0409748D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP1855715B1 (en) | 2005-01-27 | 2013-03-13 | Children's Hospital & Research Center at Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
RU2477145C2 (ru) | 2008-05-30 | 2013-03-10 | ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения |
GB0816284D0 (en) | 2008-09-05 | 2008-10-15 | Nat Biolog Standards Board | Vaccine |
ES2744471T3 (es) | 2010-09-04 | 2020-02-25 | Glaxosmithkline Biologicals Sa | Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico |
AU2011300418B2 (en) | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
-
1999
- 1999-11-29 GB GBGB9928196.6A patent/GB9928196D0/en not_active Ceased
-
2000
- 2000-11-29 CN CN200910170925.XA patent/CN101822830B/zh not_active Expired - Fee Related
- 2000-11-29 EP EP10178472A patent/EP2289599A3/en not_active Ceased
- 2000-11-29 AT AT00981554T patent/ATE427756T1/de active
- 2000-11-29 CA CA2762106A patent/CA2762106C/en not_active Expired - Fee Related
- 2000-11-29 CN CN2009100081173A patent/CN101549154B/zh not_active Expired - Fee Related
- 2000-11-29 RU RU2002117307/13A patent/RU2361609C2/ru not_active IP Right Cessation
- 2000-11-29 MX MXPA02005322A patent/MXPA02005322A/es active IP Right Grant
- 2000-11-29 EP EP00981554A patent/EP1235589B1/en not_active Expired - Lifetime
- 2000-11-29 ES ES00981554T patent/ES2322753T3/es not_active Expired - Lifetime
- 2000-11-29 US US10/148,533 patent/US9636393B2/en active Active
- 2000-11-29 CN CNB008187126A patent/CN100551441C/zh not_active Expired - Fee Related
- 2000-11-29 PT PT00981554T patent/PT1235589E/pt unknown
- 2000-11-29 CA CA2392880A patent/CA2392880C/en not_active Expired - Fee Related
- 2000-11-29 NZ NZ519608A patent/NZ519608A/en not_active IP Right Cessation
- 2000-11-29 JP JP2001539477A patent/JP5670003B2/ja not_active Expired - Fee Related
- 2000-11-29 DE DE60041981T patent/DE60041981D1/de not_active Expired - Lifetime
- 2000-11-29 WO PCT/IB2000/001940 patent/WO2001037863A2/en active IP Right Grant
- 2000-11-29 BR BR0015958-1A patent/BR0015958A/pt not_active Application Discontinuation
- 2000-11-29 CN CNA2003101046748A patent/CN1507916A/zh active Pending
- 2000-11-29 NZ NZ529213A patent/NZ529213A/en not_active IP Right Cessation
- 2000-11-29 EP EP07076133A patent/EP1902726A3/en not_active Withdrawn
- 2000-11-29 RU RU2009105117/10A patent/RU2508122C2/ru not_active IP Right Cessation
- 2000-11-29 DK DK00981554T patent/DK1235589T3/da active
- 2000-11-29 AU AU18785/01A patent/AU784375B2/en not_active Ceased
-
2009
- 2009-07-03 CY CY20091100703T patent/CY1109202T1/el unknown
-
2010
- 2010-01-29 AU AU2010200336A patent/AU2010200336B2/en not_active Ceased
-
2011
- 2011-02-15 JP JP2011030293A patent/JP2011093942A/ja not_active Withdrawn
-
2013
- 2013-11-08 JP JP2013232012A patent/JP2014028863A/ja active Pending
-
2015
- 2015-12-15 JP JP2015243752A patent/JP2016041752A/ja not_active Withdrawn
-
2017
- 2017-07-07 JP JP2017133902A patent/JP2017178971A/ja active Pending
Non-Patent Citations (4)
Title |
---|
Control testing of combined vaccines: a considerationofpotential problems and approaches.. Corbel M J.Biologicals,Vol.22 No.4. 1994 |
Control testing of combined vaccines: a considerationofpotential problems and approaches.. Corbel M J.Biologicals,Vol.22 No.4. 1994 * |
Prophylaxis of bacterial meningitis.. Peltola H.Infectious Disease Clinics of North America,Vol.13 No.3. 1999 |
Prophylaxis of bacterial meningitis.. Peltola H.Infectious Disease Clinics of North America,Vol.13 No.3. 1999 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100551441C (zh) | 包含脑膜炎奈瑟球菌血清群b和c抗原和其它抗原的组合物 | |
ES2387592T5 (es) | Vacunas combinadas contra Neisseria meningitidis | |
CN100579580C (zh) | 粘膜脑膜炎球菌疫苗 | |
RU2323002C2 (ru) | Вакцины, содержащие алюминиевые адъюванты и гистидин | |
ES2423019T3 (es) | Mejora de las vesículas de membrana externa bacteriana | |
EP2327719B1 (en) | Hybrid and tandem expression of neisserial proteins | |
JP2009155344A (ja) | アジュバント化された抗原性髄膜炎菌性組成物 | |
AU2013206190A1 (en) | Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen | |
CN103933559B (zh) | 志贺氏菌多价结合疫苗 | |
AU2006202664B2 (en) | Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Italy Siena Patentee after: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. Address before: Italy Siena Patentee before: CHIRON S.R.L. Address after: Italy Siena Patentee after: CHIRON S.R.L. Address before: Italy Siena Patentee before: CHIRON S.P.A. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170728 Address after: Belgium Sutter Rixon Patentee after: GLAXOSMITHKLINE BIOLOGICALS S.A. Address before: Italy Siena Patentee before: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091021 Termination date: 20171129 |